Sodium polystyrene sulfonate


Concise Prescribing Info
Indications/Uses
Hyperkalaemia.
Dosage/Direction for Use
Adult : PO 15 g up to 4 times/day. Rectal As enema (susp): 30 g retained for at least 9 hr if possible. Higher doses may be retained for a shorter period of time.
Dosage Details
Oral
Hyperkalaemia
Adult: As suspension in water or syrup or as sweetened paste: 15 g up to 4 times daily. Not to be taken with fruit juices that have high potassium content.
Child: Acute hyperkalaemia: 1 g/kg daily in divided doses. Maintenance: 500 mg/kg daily.

Rectal
Hyperkalaemia
Adult: As enema (suspension): 30 g in 100 ml of 2% methylcellulose '450' and 100 ml of water, retained for at least 9 hr, if possible. Higher doses may be retained for a shorter period of time. Irrigate colon after retention to remove the resin.
Child: and neonates: Acute hyperkalaemia: 1 g/kg daily in divided doses. Maintenance: 500 mg/kg daily.
Contraindications
Oral admin to neonates; neonates with reduced gut motility; obstructive bowel disease. Hypokalaemia.
Special Precautions
Renal failure and conditions requiring a restricted sodium intake e.g. heart failure and severe hypertension. Rectal admin to neonates and children. Monitor for electrolyte disturbances and symptoms of hypokalaemia. Discontinue treatment if clinically significant constipation develops. Irrigate colon after admin of enema to ensure removal of resin. Pregnancy; lactation.
Adverse Reactions
Anorexia, nausea, vomiting, constipation, faecal impaction, diarrhoea; hypokalaemia; hypocalcaemia; sodium retention in patients with impaired renal function.
Overdosage
Overdosage may lead to signs and symptoms of hypokalaemia e.g. irritability, confusion, delayed thought processes, muscle weakness, hyporeflexia, which may progress to frank paralysis and/or apnea. Cardiac arrhythmias may occur. Appropriate measures include correcting serum electrolytes (potassium, calcium), and removing resin from the GI tract by laxatives or enemas.
Drug Interactions
Reduces absorption of thyroxine and lithium salts. Enhances adverse effects of cardiac glycosides. Potassium-lowering effect may be reduced when used with other cation-containing antacids.
Action
Description: Sodium polysytrene sulfonate exchanges sodium ions for potassium ions and other cations in the GI tract before the resin is excreted in the faeces.
Onset: 2-24 hr.
Pharmacokinetics:
Excretion: Exchanged resin eliminated in the faeces.
Storage
Store at 15-30°C.
Disclaimer: This information is independently developed by MIMS based on Sodium polystyrene sulfonate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in